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Objective: To determine the prevalence of poor response to aspirin (ASA) therapy over 12-month follow-up in patients with lower
extremity peripheral arterial disease (PAD), and to compare the classification agreement among different ASA response assays.
Methods: Patients with PAD on ASA therapy at baseline were included from the ongoing Effect of Lipid Modification on
Peripheral Arterial Disease after Endovascular Intervention Trial (ELIMIT), which is a randomized trial testing whether
combination treatment with ezetimibe, niacin, and a statin will halt/regress atherosclerosis compared with statin
monotherapy. Patients who had baseline platelet testing and repeat testing at 6-month or 12-month follow-up were
included. ASA responsiveness was tested using three different assays: Optical aggregation with 0.5mg/mL of arachidonic
acid (AA), optical aggregation with 10 M of adenosine diphosphate (ADP), and platelet function analyzer-100
(PFA-100) testing with collagen/epinephrine (Epi) loaded cartridges. ASA response was defined as AA aggregation
<30%, ADP aggregation <70%, or PFA-100 Epi >164 seconds. Patients who showed response to ASA at baseline were
classified as Responders. Poor response to ASA was defined as AA aggregation >30%, ADP aggregation >70%, or
PFA-100 Epi <164 seconds. Patients who showed poor response (PR) to an assay at baseline, but then were responsive
at follow-up visits were classified as Initial PRs. Patients who showed poor response at baseline and all follow-up visits
were classified as Persistent PRs. The classification agreement between assays was tested using the kappa statistic.
Results:Of 102 patients randomized in ELIMIT, 80 patients satisfied inclusion criteria. There were no significant baseline
demographic differences between Responders, Initial PRs, and Persistent PRs. The prevalence of persistent poor response
varied by the assay used; 5% of subjects (4/80) were Persistent PRs by AA aggregation, compared with 27.5% (22/80)
of subjects by ADP aggregation and 9.9% (7/71) of patients by PFA-100 Epi. Regarding the agreement of the assays, only
AA aggregation and PFA-100 Epi agreed significantly (K  0.3223; 95% confidence interval [CI] 0.15-0.493; P 
.0001), and though statistically significant, the magnitude of this agreement is small. AA aggregation and ADP
aggregation did not agree (K  0.1161; 95% CI 0.004-0.236; P  .029), nor did ADP aggregation and PFA-100 Epi
(K  0.0044; 95% CI 0.151-0.160; P  .48).
Conclusions: Between 5% and 27.5% of PAD patients were Persistent PRs to ASA over 6- to 12-month follow-up using
different platelet assays. Further, these commonly used platelet assays showweak agreement in determining poor response
to aspirin. (J Vasc Surg 2011;53:668-75.)
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CAspirin (ASA) therapy is recommended for adverse
cardiovascular event risk reduction in patients with athero-
sclerosis including peripheral arterial disease (PAD),1 but
many patients still develop atherothrombotic events despite
ASA therapy,2,3 and cardiovascular events remain a major
cause for morbidity and mortality in PAD patients. Poor
anti-platelet response to ASA may explain some of the
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Volume 53, Number 3 Saunders et al 669used.6,7 Poor ASA response has been associated with hy-
peractive platelets in CAD patients,8 and we have previ-
ously shown that platelets from PAD patients are more
hyperactive than the platelets from CAD patients.9 There is
poor agreement among commonly used platelet response
assays,10,11 thus it is unclear which assay is most reliable for
identifying subjects at risk for future death, MI, or stroke.
As there are limited reports on the agreement of the assays
in PAD patients over time, we sought to determine the
prevalence of persistent poor response to ASA over long-
term follow-up in patients with PAD and to assess the
agreement between commonly used assays of platelet re-
sponse to ASA.
METHODS
We evaluated the prevalence of poor response to ASA
therapy in a PAD cohort from the Effect of Lipid Mod-
ification on Peripheral Arterial Disease after Endovascu-
lar Intervention Trial (ELIMIT; clinical trials identifier
NCT00687076, grant funding R01 HL075824), which
is a randomized, double-blinded, placebo-controlled trial
approved by the Institutional Review Board at our institu-
tions, that tests whether combination treatment with a
statin, ezetimibe, and niacin will halt/regress the progres-
sion of atherosclerosis compared with statin monotherapy.
The ELIMIT recruited subjects aged 40 to 80 years of age
with a history of symptomatic femoral atherosclerosis and
ankle-brachial index 0.9 or imaging results confirming
femoral artery occlusive disease.12 After inclusion in the
study, subjects underwent percutaneous transluminal an-
gioplasty (PTA) with or without stenting. The effect of
lipid-lowering therapy on thrombosis parameters is a
planned secondary outcome measure. For our analysis, we
included subjects on ASA who underwent baseline platelet
testing and at least one other follow-up platelet testing
(either 6-month and/or 12-month follow-up).
Blood collection
After an overnight (8 hours) fast, and at least 4 hours
since last smoking, patients underwent phlebotomy with
either a 19-gauge or 21-gauge needle with syringe to
reduce effects of high fluid shear stress on platelet function.
Sodium citrate (0.38% final concentration) was used as an
anticoagulant. The first 2 mL of blood was discarded to
reduce injury-related platelet reactivity. All platelet func-
tion assays were performed on the same vial of blood.
Whole blood was directly used for assays by the Platelet
Function Analyzer (PFA-100; Dade-Behring, Deerfield,
Ill). For the optical aggregation studies, platelet-rich
plasma (PRP) was collected by centrifuging whole blood at
150  g for 15 minutes at 25oC. The arachidonic acid-
induced aggregation was performed with undiluted PRP
according to themanufacturer’s instruction. The adenosine
diphosphate (ADP)-induced aggregation was performed
with PRP normalized at 2.0 to 2.5  108 platelets/mL.
The assays were performed within 2 hours of sample col-
lection. rlatelet function assays
Optical aggregation tests utilized either of the follow-
ng agonists: 0.5 mg/mL of arachidonic acid (AA; BioData
orp, Horsham, Pa) or 10 Mof ADP (Sigma-Aldrich, St.
ouis, Mo), and was measured on an optical PAP-4 ag-
regometer (BioData Corp). Platelet aggregation was
onitored for 10 minutes at 37oC with constant stirring
1,000 rpm). For the PFA-100 assays, 0.8 mL of citrated
hole blood was loaded into a collagen and epinephrine
Epi)-coated cartridge that has an aperture allowing blood
o pass through. The time required to occlude the aperture
as measured and reported as closure time (CT, seconds).
There are several reasons for selecting these platelet
unction assays. AA is a precursor of thromboxane A2 that
ctivates platelets through COX-1-dependent pathway,
hich is targeted by ASA. The AA aggregation assay there-
ore measures the degree of platelet inhibition due to ASA.
he ADP-induced platelet aggregation by activating plate-
et ADP receptors was also measured for two reasons. First,
DP is released from activated platelets to propagate or
nhance platelet aggregation induced by a primary agonist
uch as AA (secondary aggregation). Second, there are early
eports that AA-induced platelet aggregation is mediated
y or synergized with ADP.13,14 The PFA-100 assays plate-
et activation, aggregation, and thrombus formation in
esponse to shear stress and exposure to collage and Epi.
hus, these assays provide perspective on multiple path-
ays that lead to platelet aggregation.
For AA aggregometry, poor response to ASA was de-
ned as 30% aggregation. For ADP aggregometry, poor
SA response was defined as 70% aggregation. Poor
esponse to ASA was defined as CT 164 seconds for the
pi cartridge. The thresholds we have used are based on
nalysis of 400 normal controls from our lab (data not
hown). For quality control, 10% of samples were dupli-
ated, and all equipment underwent daily calibration before
ample analyses. Our definition is similar to those used in
ther studies of PFA-10015 and ADP aggregometry,16
hereas our definition of ASA non-response by arachidonic
cid aggregometry is more restrictive than that used in the
tudy by Gum et al.16
tatistical methods
A subject was classified by ASA response into one of
hree different categories based on the results of each
ndividual platelet assay. Therefore, a single subject could
e categorized differently by the different assays. The three
ategories were ASA “Responders,” “Initial Poor Respond-
rs (PRs),” or “Persistent PRs.” These categories were
ssessed separately for each test and for the composite of all
ests.
Subjects were classified as ASA Responders if baseline
latelet aggregation to arachidonic acid was 30%, or
ggregation to ADP was 70%, or baseline PFA-100 Epi
T was164 seconds. If a subject initially showed respon-
iveness to an assay, they were classified as a Responder
egardless of follow-up testing, since the primary aim of our
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March 2011670 Saunders et alstudy was to identify the prevalence of Persistent PRs. It
was common for subjects to change from responsive to
non-responsive (see Results for full description).
Initial PRs had baseline AA aggregometry30%, ADP
aggregometry 70%, or PFA-100 Epi 164 seconds. On
subsequent follow-up testing, the Initial PRs showed ap-
propriate ASA response (AA aggregometry 30%, ADP
aggregometry 70%, or PFA-100 Epi 164 seconds).
Persistent PRs had baseline poor response (AA ag-
gregometry30%, ADP aggregometry70%, or PFA-100
Epi 164 seconds) and continued to show poor response
at all follow-up tests in the same assay.
Baseline demographic and historical data were col-
lected and compared between Responders, Initial PRs,
and Persistent PRs for AA aggregometry using the non-
parametric Kruskal-Wallis test for continuous data, and 2
test or Fisher’s exact test for categorical data where appro-
priate. Repeated follow-up measurements from each assay
type were compared with their own baseline measurements
with Spearman rank correlation. The classification agree-
ment for poor responders based on different assays was
calculated both as a raw percentage agreement and with the
kappa statistic. For subjects where there was only one assay
result, the pair was dropped from the comparison so that
the number of results compared was equal.
RESULTS
Of the 102 patients initially randomized in the
ELIMIT trial, 80 subjects met qualifications for inclusion
in the analysis. Among the 22 patients excluded, four
patients lacked a baseline sample for platelet testing, and 18
subjects did not have follow-up testing after baseline. In
total, all 80 included subjects had platelet testing at baseline
and at least one follow-up visit. Optical aggregometry for
both AA and ADP was available for 72 patients at 6-month
follow-up, and 65 patients at 12-month follow-up. There
were fewer PFA-100 results than optical aggregometry
results as blood samples sometimes obstructed the PFA
system, and hence, could not be evaluated. For PFA-100
Epi testing, there were 71 samples at baseline, 67 samples at
6-month follow-up, and 59 at 12-month follow-up. Sub-
jects without baseline PFA-100 measurement were ex-
cluded in analysis of PFA-100 Epi classification and vari-
ability, but they were not excluded from analysis of AA- and
ADP-induced platelet aggregation.
Baseline demographic data for the overall study popu-
lation are reported in Table I, and baseline demographic
data comparing ASA Responders to Initial PRs and to
Persistent PRs for each assay are presented in Table II. As
there were a small number of women (n  5) in the study,
we assessed the baseline demographics with and without
women. The findings were the same; thus, we report anal-
ysis for the entire 80 subjects. Overall, the baseline charac-
teristics of Responders, Initial PRs, and Persistent PRs were
similar. In all three assays, the persistent PRs had higher age
and higher hsCRP value, but these differences were not
statistically significant secondary to the small number of (atients in the Persistent PRs subset. The individual assay
nformation is reported below.
rachidonic-acid aggregometry
By AA aggregometry, 15/80 (18.8%) subjects showed
SA poor-response at baseline. In follow-up testing,
1/80 (13.8%) of those showed response to ASA at
-month follow-up and were classified as Initial PR (Fig 1).
our subjects (5%) remained as Persistent PRs 12 months
fter initial testing. Baseline demographic characteristics
ere generally similar between the three response catego-
ies. There were differences in the proportion of subjects
ith a history of diabetes (P .01) with a larger proportion
f Responders having diabetes compared with the Initial
Rs (P .006). To measure the repeatability of the tests at
ifferent time points, Spearman rank correlations (Table
II) were computed between baseline and follow-up values.
or AA-induced aggregation, the 6-month follow-up test
ositively correlated with the baseline measurement (r 
.44, P  .0001). Similarly, the 12-month follow-up cor-
elation with baseline AA aggregation was also statistically
ignificant (r  0.35, P  .0039).
denosine diphosphate aggregometry
The ADP-induced platelet aggregation classified the
ighest number of subjects as Persistent PRs. By this assay,
7 of 80 subjects (58.8%) were identified as Initial PRs, and
2 of 80 (27.5%) remained Persistent PRs at follow-up
able I. Baseline demographic information for overall
tudy cohort
emographic information
ge (years) 64.7 (42.8-85.1)
ender (% male) 93.8
ace (%)
White, not of Hispanic origin 70
Black, not of Hispanic origin 18.8
Hispanic 11.3
istory of smoking (%) 91.3
urrently smoking (%) 45.2
ast medical history
Hypertension (%) 82.5
Hyperlipidemia (%) 92.5
Coronary artery disease (%) 21.3
Stroke (%) 16.3
Diabetes (%) 39.2
spirin dose (% on 325 mg) 85
aseline medications
Clopidogrel (% taking) 26.3
Statin (% taking) 97.5
ody mass index (kg/m2) 29.8 (18.0-53.8)
ystolic blood pressure (mm Hg) 138 (92-199)
iastolic blood pressure (mm Hg) 74.5 (48-98)
otal cholesterol (mg/dL) 166 (106-337)
riglycerides (mg/dL) 140 (43-1986)
igh-density lipoprotein cholesterol (mg/dL) 40 (19-85)
ow-density lipoprotein cholesterol (mg/dL) 92 (49-244)
sCRP (mg/L) 2.96 (0.35-68.1)
ontinuous variables are indicated with median (range).Fig 1). There were no significant baseline demographic
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Volume 53, Number 3 Saunders et al 671differences between the three response groups by ADP
aggregation (Table II). The 6-month follow-up test (r
0.49, P  .0001) showed a moderate but significant
correlation with baseline values. On the other hand,
12-month values (r  0.20, P  .1063) were not signif-
icantly correlated with baseline measurements. Although
a larger number of subjects were defined as Persistent
PRs when defined by ADP-induced platelet aggregation.
These subjects often did not meet criteria for persistent
non-response by any other assay (Fig 2).
Platelet function analyzer-100 Epi
The PFA-100 Epi assay classified 27 of 71 (38.0%)
Table II. Baseline demographic information by response c
AA aggregometry (n  80) Responders (n  65)
Age (years) 64.7
Race (% Black, White, Hispanic) 19, 68, 13
ASA dose (% 325 mg) 86
Clopidogrel use (%) 26
NSAID use (%) 18
History of smoking (%) 92
Current smoking (%) 45
Hypertension (%) 82
Coronary artery disease (%) 22
Diabetes (%) 47
Body mass index (kg/m2) 29.8
Hematocrit (%) 40.9
hsCRP (mg/L) 2.83
ADP aggregometry (n 80) Responders (n  33)
Age (years) 64.8
Race (% Black, White, Hispanic) 15, 79, 6
ASA dose (% 325 mg) 82
Clopidogrel use (%) 36
NSAID use (%) 9
History of smoking (%) 91
Current smoking (%) 50
Hypertension (%) 82
Coronary artery disease (%) 18
Diabetes (%) 42
Body mass index (kg/m2) 29.2
Hematocrit (%) 41.6
hsCRP (mg/L) 2.73
PFA-100 Epi (n  71) Responders (n  44)
Age (years) 64.6
Race (% Black, White, Hispanic) 25, 61, 14
ASA dose (% 325 mg) 86
Clopidogrel use (%) 25
NSAID use (%) 20
History of smoking (%) 91
Current smoking (%) 43
Hypertension (%) 82
Coronary artery disease (%) 30
Diabetes (%) 40
Body mass index (kg/m2) 29.8
Hematocrit (%) 41.3
hsCRP (mg/L) 2.93
AA, Arachidonic acid; ADP, adenosine diphosphate; ASA, aspirin; Epi, epi
analyzer.subjects as Initial PR, and of those, 7 of 71 (9.9%) remained sersistent PRs (Fig 1). Of note, two subjects who did not
ave baseline values reported, had both 6-month and 12-
onth follow-up values that were responsive, were not
ncluded in the analysis. There were no significant baseline
emographic differences between the response categories
efined by the PFA-100 Epi assay (Table II). This assay
howed the weakest correlation on repeat testing and found
o significant correlation between baseline and 6-month
r  0.03, P  .798), or baseline and 12-month
r  0.16, P  .2518) follow-up values.
ariability and classification agreement
Responders. At the baseline visit, 65 of 80 (81.2%)
ory among the different assays
Initial PR (n  11) Persistent PR (n  4) P
63.6 67.6 .31
9, 91, 0 50, 50, 0 .23
91 50 .12
36 0 .37
9 0 .84
82 100 .43
56 25 .65
82 100 .64
18 25 .93
0 25 .01
31.7 26.5 .33
52.5 35.8 .02
2.98 4.27 .61
Initial PR (n  25) Persistent PR (n  22) P
62.9 65.7 .50
20, 60, 20 23, 68, 9 .44
92 82 .50
28 9 .08
7 27 .20
92 91 .99
43 40 .77
84 82 .97
28 18 .73
38 36 .88
32.4 31.5 .18
44.3 39.95 .63
2.93 3.87 .70
Initial PR (n  20) Persistent PR (n  7) P
63.5 66.4 .55
15, 80, 5 14, 72, 14 .64
75 86 .52
35 14 .52
20 0 .59
95 86 .73
58 33 .52
80 86 .94
15 14 .46
30 57 .44
28.9 31.3 .60
39.3 42.3 .80
2.73 3.43 .49
ine; NSAID, nonsteroidal anti-inflammatory drugs; PFA, platelet functionateg
nephrubjects were classified as Responders by AA aggregation,
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March 2011672 Saunders et al33 of 80 (41.2%) subjects by ADP aggregation, and 44 of
71 (62.0%) subjects by PFA-100 Epi. Only 15 subjects
were classified as a Responder by all three assays at baseline.
Of those 15 Responders, only seven were found to be
responsive at baseline and all follow-up time points tested.
For the individual assays, there was variability in the re-
sponse status as well. Of the 65 subjects identified as
Responders by AA aggregation at baseline, 59 of 65
(90.8%) were found to be responsive at all time points
tested. For ADP aggregation, 23 of 33 (69.7%) of the
Responders at baseline remained responsive at all time
points, and for PFA-100 Epi, 27 of 44 (61.4%) of subjects
were responsive at all time points tested.
Persistent Poor Responders. A total of 26 subjects
were identified as Persistent PRs by any of the three assays,
but only six of those satisfied criteria for two assays, and
only one subject satisfied criteria for Persistent PR for all
three assays. Fig 2 depicts the overlap in patients identified
as Persistent PR by the various assays. Although few pa-
tients were persistently poor responders, the majority of
Fig 1. Proportion of responders (light gray), Initial Poor Respond-
ers (PRs) (darker gray), and Persistent PRs (gray stripe) are depicted.
Numbers listed within each bar refer to number of subjects in that
category. N 80 total for arachidonic acid (AA)-aggregometry and
adenosine diphosphate (ADP)-aggregometry; N 71 total for Plate-
let Function Analyzer (PFA)-100 Epi.
Table III. Correlation coefficients, number of subjects,
and P values for statistical significance
Correlation
coefficient (r) P value
Baseline AA aggregometry (agg)
6 months AA agg (n  72) 0.44 .0001
12 months AA agg (n  65) 0.35 .0039
Baseline ADP aggregometry (agg)
6 months ADP agg (n  72) 0.49 .0001
12 months ADP agg (n  65) 0.20 .1063
Baseline PFA-100 Epi
6 months PFA Epi (n  67) 0.03 .7980
12 months PFA Epi (n  59) 0.16 .2518
AA,Arachidonic acid;ADP, adenosine diphosphate; Epi, epinephrine; PFA,
platelet function analyzer.subjects (91.25%) had at least a single poor response to one nf the assays at one point during the study when the various
ests were pooled, indicating that a patient’s platelet re-
ponsiveness to ASA may be a dynamic one with a small
umber of patients who are persistently poor responders, or
hat patient non-compliance is a significant issue.
The agreement between the assays was assessed
hrough raw percentage agreement and though the calcu-
ation of the kappa statistic. Results are summarized in
able IV with kappa statistics for each comparison and P
alues for significance listed in each box. The AA aggrega-
ion and PFA-100 Epi assays showed the highest raw
greement at 69% and the highest kappa statistic value (K
.3223; 95% confidence interval [CI] 0.152-0.493; P 
0001). However, this is only “fair” agreement according
o published scales.17 The comparison between ADP-
nduced aggregation and PFA-100 Epi had a raw agree-
ent of 36.6% and non-significant kappa statistic (K 
.0044). Similarly, the comparison between ADP- and
A-induced platelet aggregation had a raw agreement of
6.3% and very slight agreement by kappa statistic (K 
.1161).
ISCUSSION
In our analysis of platelet function assays in PAD pa-
ients on ASA, there are several major findings: First, 5% to
7.5% of PAD patients may be classified as Persistent PRs to
SA depending on the type of platelet assay used. Second,
hough some patients could be defined as poor responders
y single testing, they could be found to be responsive
hrough subsequent testing or through using a different
latelet assay. This suggests that either platelet responsive-
ig 2. Venn diagram of the overlap in classification of Persistent
oor Responders (PRs) by the three assays tested. The numbers
ithin the circles represent the numbers of subjects satisfying
riteria for persistent PR by the particular assay. Subjects who
atisfied two definitions of persistent PR are in the overlapping
reas of the circles. One subject satisfied all three criteria for
ersistent PR and is shown in the overlap of all three circles.ess to ASA is dynamic with several activation pathways
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Volume 53, Number 3 Saunders et al 673subject to change in response to patients’ conditions and
treatments, or that compliance with therapy is a major issue
in determining ASA responsiveness. Third, the classifica-
tion agreement and correlation between these three widely
used platelet assays is poor in terms of identifying patients as
being poor responders to ASA. In total, these data call into
question the usefulness of a single test at a single time to
determine a patient’s ASA responsiveness, and the utility in
using these assays to identify subjects at higher risk for
future vascular events.
The prevalence of poor response to ASA in our study
population is higher than has been seen in primary preven-
tion populations,11 but is similar to that seen in prior PAD
studies18 and stable cardiovascular disease patients.19How-
ever, most studies have used a single measurement of
platelet function to determine a subject’s responsiveness.
There are limited data on the agreement of different plate-
let function assays over time. In survivors of acute myocar-
dial infarctions, Andersen and colleagues randomized 202
patients to high- or low-dose aspirin and Coumadin com-
binations and assessed platelet function by PFA-100. They
found some stability in the PFA-100 measure over time
with only 10% of subjects changing their responsiveness
category.20 In contrast, patients with a history of stroke
were assessed by Helgason et al, where it was found that
33% of subjects who initially were aspirin responders lost
some of their responsiveness at follow-up platelet testing.3
Similarly, Harrison and colleagues found that, in stroke
patients, aspirin non-response at 1-year follow-up was vari-
able based on light transmission aggregometry, PFA-100,
or the VerifyNow ASA assay.21 These studies did not
include large numbers of subjects with lower extremity
PAD. To our knowledge, only one other study of PAD
patients used repeated platelet function testing during
long-term follow-up.18 In their study, Linneman et al
reported poor response to ASA occurred in 4.1% of those
patients by aggregometry, but it did not persist in any at
both baseline and follow-up. While they assessed the cor-
relation within a given assay at baseline and follow-up, the
classification agreement between different assays was not
described. We have found that there are a small number of
patients who have persistently abnormal values over 6- to
12-month follow-up. Further, only 60% to 90% (28.8% to
74.4% of the overall study population) of those originally
found to be ASA responders remained so, again emphasiz-
Table IV. Kappa statistic for comparisons between assays
Arachidonic acid
ADP aggregometry K  0.1161
(0.004–0.236)
46.3% positive
PFA-100
Epinephrine
K  0.3223
(0.152–0.493), P
69% positive
ADP, Adenosine diphosphate; PFA, platelet function analyzer.ing that ASA response is a changing variable, but the cause nor the variation is not fully understood. Nevertheless, the
onsiderable variation does call for evaluating the state of
latelet inhibition by ASA by multiple tests at multiple time
oints.
A strong message from this study is that there are
ndividuals who have persistent poor response to ASA.
here are several potential mechanisms beyond non-
ompliance that may account for poor response to ASA
herapy as seen in our PAD patients. First, 26% of subjects
ere on clopidogrel, and while the difference in clopidogrel
se was not significantly different between responders and
oor responders, the persistent poor responders had the
owest clopidogrel use. However, a recent study of clopi-
ogrel use in aspirin resistant subjects by Fontana22 dem-
nstrated no effect of clopidogrel on aspirin resistance or
seudoresistance. Thus, while our data are in limited num-
ers, they suggest that PAD subjects on dual antiplatelet
herapy achieve greater inhibition as measured by platelet
unction assays. Second, poor response to ASA may result
rom either the failure to inhibit TXA2 production through
he COX-1 pathway, or persistence of platelet aggregation
ue to COX-1 independent pathways. ASA may fail to
ompletely inhibit COX-1 mediated TXA2 if the platelets
re in a hyperactive state23 or are reticulated,8 both of
hich are associated with PAD.9,24,25 We have previously
hown that reticulated platelets have incomplete COX-1
nhibition in response to ASA therapy.26 Finally, a persis-
ently poor response to ASA could also be caused by genetic
actors, which have been implicated in studies focusing on
nown SNPs of selected molecules.27-29 However, these
tudies may not be sufficient to distinguish between genetic
nd acquired factors associated with ASA response because
hey often focused on individuals with high risk for cardio-
ascular diseases. An unbiased genomic study on young
ubjects without confounding diseases may be needed to
dentity genetic factors associated with ASA response.
In our current analysis, we have established that these
ssays measure different aspects of platelet activity, and also
hat they identify individuals differently. Aspirin respon-
iveness is often considered as a dichotomous variable;30
owever, the true likelihood is that responsiveness is a
ontinuum and reflects the responsiveness of multiple in-
ersecting platelet aggregation pathways. As a result, we
ould hypothesize that each of these assays offers clinically
elevant data, but that the overall picture of responsiveness
gometry ADP aggregometry
0.029
.0001
K  0.0044
(0.151–0.160), P  0.48
36.6% positiveaggre
, P 
 0eeds to be established through multiple testing or at
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March 2011674 Saunders et alseparate time points. Specifically in subjects with PAD, the
data are even more limited. Based on our data, we cannot
say that any single test is clinically beneficial in identifying a
group of subjects unless it is tested on more than one
occasion, or multiple tests are used.
LIMITATIONS
Our study has several limitations. First, we did not
examine all assays of ASA response including measurement
of urine thromboxane B2 (TXB2). Elevated levels of TXB2
in patients who are on ASA therapy are a marker of poor
response, and have been associated with increased cardio-
vascular events.4 Second, the ELIMIT is still ongoing, thus
the impact of the blinded lipid treatment assignment on
follow-up platelet assay results is not known. While statin
therapy reduces platelet aggregation,31-33 all subjects were
on statin therapies, and this is unlikely to account for our
findings. Both ezetimibe34 and niacin35 are associated with
improved platelet aggregation, but the effects of blinded
treatments cannot yet be ascertained. Of note, a recent
study demonstrated minimal changes in aggregation when
ezetimibe was added to simvastatin, but the effect of niacin
when combined with statin therapy has not yet been eval-
uated. Third, we do not have information on the type of
ASA taken. The use of enteric-coated ASA has been asso-
ciated with more frequent findings of poor response to ASA
in both healthy people36 and in subjects with stable cardio-
vascular disease.37 Additionally, we do not have data on
proton-pump inhibitor medication use, which has recently
been associated with reduced aspirin effect,38 but as the
proportion of our population that is classified as persistent
poor responders is similar to prior studies, this is unlikely to
have exerted a large effect. Last, patient non-compliance
may still exert a significant effect on these assays. Although
these patients are enrolled in a clinical trial, we did not
directly observe the ASA dose timing or type of ASA taken;
however, this is a problemwithmany clinical studies of ASA
treatment.Weminimized this effect through the use of very
restrictive criteria for poor response.
CONCLUSIONS
Between 5% and 27.5% of the symptomatic PAD pop-
ulation is persistently non-responsive to ASA therapy when
measured by AA aggregometry, ADP aggregometry, or
PFA-100 Epi. Individual platelet function assays do not
correlate well, highlighting the difficulty in developing a
standard laboratory assessment for platelet response to
ASA. The clinical implications of these data suggest poten-
tial benefit in using different assay types, or using repeated
assays over time to evaluate a patient’s antiplatelet response
to aspirin. Further, our data serve as caution to defining
ASA response on the basis of a single assay.
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